Smaller drugmakers beat Big Pharma in partnering popularity contest

Big Pharma companies aren't the most popular partners for biotechs looking to out-license products, a Boston Consulting survey found. Even top-scoring GlaxoSmithKline ($GSK) has moved down in the ranks, as smaller drugmakers like Celgene ($CELG) and Novo Nordisk ($NVO) moved up to first and second place. Report